Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

ACTU

Actuate Therapeutics Inc.

Oct 11 • 04:00PM ET

7.35

Dollar change +0.19
Percentage change 2.65	%

Healthcare • Biotechnology • USA • NASD

Peers: BNTX GILD JNJ LLY MRK MRNA NVAX PFE REGN VIR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	69.92%	Shs Outstand	19.11M	Perf Week	-1.47%
Market Cap	140.46M	Forward P/E	-	EPS next Y	-	Insider Trans	11.76%	Shs Float	5.75M	Perf Month	-7.55%
Income	-	PEG	-	EPS next Q	-	Inst Own	-	Short Float	0.23%	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.31	Perf Half Y	-
Book/sh	-5.85	P/B	-	EPS next Y	-	ROA	-	Short Interest	0.01M	Perf Year	-
Cash/sh	0.02	P/C	401.31	EPS next 5Y	-	ROE	-	52W Range	5.51 - 10.16	Perf YTD	-14.63%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-27.67%	Beta	-
Dividend TTM	-	Quick Ratio	0.03	Sales past 5Y	0.00%	Gross Margin	-	52W Low	33.39%	ATR (14)	0.64
Dividend Ex-Date	-	Current Ratio	0.03	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	49.74	Volatility	6.81% 9.92%
Employees	-	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-	Payout	-	Rel Volume	0.55	Prev Close	7.16
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	42.58K	Price	7.35
SMA20	3.06%	SMA50	-5.14%	SMA200	-5.14%	Trades		Volume	23,522	Change	2.65%

Sep-23-24 08:00AM	Actuate Announces Scientific Reports Publication on Elraglusib's Novel Immunomodulatory Mechanism of Action as a GSK-3 Inhibitor (GlobeNewswire) -8.89%
Sep-16-24 08:00AM	Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research (GlobeNewswire)
Sep-11-24 08:00AM	Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas (GlobeNewswire)
Sep-09-24 08:00AM	Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma (GlobeNewswire)
Sep-05-24 09:10AM	Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
09:00AM	Loading…
Aug-20-24 09:00AM	Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024 (GlobeNewswire)
Aug-14-24 04:05PM	Actuate Therapeutics Announces Closing of Initial Public Offering (GlobeNewswire) +6.27%
Aug-12-24 08:27PM	Actuate Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)
May-28-24 07:00AM	Actuate Therapeutics Files Registration Statement for Initial Public Offering (GlobeNewswire)

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
THOMSON TODD S	16.4% Owner	Aug 14 '24	Sale	8.00	18,750	150,000	1,184,795	Aug 16 09:12 PM
Bios Equity COF, LP	Director	Aug 14 '24	Buy	8.00	500,000	4,000,000	1,259,427	Aug 14 08:54 PM
Bios Equity COF, LP	Director	Aug 14 '24	Sale	9.00	24,999	224,991	131,248	Aug 14 08:54 PM
Fletcher Aaron G.L.	Director	Aug 14 '24	Buy	8.00	500,000	4,000,000	1,259,427	Aug 14 08:49 PM
Fletcher Aaron G.L.	Director	Aug 14 '24	Sale	9.00	24,999	224,991	131,248	Aug 14 08:49 PM
Kreis Leslie W.	10% Owner	Aug 14 '24	Buy	8.00	500,000	4,000,000	1,259,427	Aug 14 08:44 PM
Kreis Leslie W.	10% Owner	Aug 14 '24	Sale	9.00	24,999	224,991	131,248	Aug 14 08:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACTU

Actuate Therapeutics Inc.

Upgrade your FINVIZ experience